Ballast小型/中型股主动型ETF MGMT 深 沪
等待开盘 07-06 09:30:00 美东时间
49.8772
-0.714
-1.41%
华盛通- 最 高50.72
- 今 开50.59
- 成交量 2887股
- 最 低 49.65
- 昨 收 50.5913
- 总市值 1.76亿
- 52周最高 51.22
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 38.7493
- 委 比 0.00%
- 总股本 352.48万
- 历史最高 51.22
- 量 比 0.62
- 振 幅 2.11%
- 历史最低 24.1332
- 每 手 1
- 风险率 2.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Apollo Confirms It Will Not Make Firm Offer For Bodycote
BRIEF-Apollo Confirms It Will Not Make Firm Offer For Bodycote June 5 (Reuters) - Apollo Global Management Inc APO.N : APOLLO MGMT. H L.P. BODYCOTE PLC - RULE 2.8 ANNOUNCEMENT APOLLO: INTENTION NOT TO MAKE AN OFFER FOR BODYCOTE PLC APOLLO - APOLLO CONFIRMS IT WILL NOT MAKE FIRM OFFER FOR BODYCOTE S
06-05 14:25
Caris study validates AI signature predicting temozolomide benefit in glioblastoma patients
Caris study validates AI signature predicting temozolomide benefit in glioblastoma patients Caris Life Sciences published peer-reviewed validation results in Neuro-Oncology Advances for an AI-derived signature intended to guide temozolomide use in glioblastoma. Study found signature aligned with sta
04-29 20:48
GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates
GEO Group reported lower Q1 revenue and adjusted EBITDA, missing consensus. EPS also fell short. Outlook raised for FY25 but Q2 expectations lowered.
2025-05-07 23:32
Shuttle Pharmaceuticals Expands Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment
Shuttle Pharmaceuticals Holdings Inc. has announced an update to its clinical trial for the drug Ropidoxuridine, a radiation sensitizing agent. The company has entered into a change order with Therade...
2025-01-29 05:11
AZZ Eyes Growth Spurt: Strong Markets Fuel FY25 Sales, Profit Forecast
AZZ raises FY25 guidance due to strength in several end markets. Sales outlook increased to $1.525-$1.625B, adjusted EPS to $4.50-$5.00, and adjusted EBITDA to $310-$360M. Company plans to report Q4 results on April 22, 2024.
2024-04-08 20:43
